Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 06 December 2017

Indication(s)

VANTAVO is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D insufficiency. It reduces the risk of vertebral and hip fractures.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hypogonadism

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more.

+ 1 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

ALP Lab Assessment

ALP Lab Assessment

Discover and overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/001180
Orphan designation No
Date First Approved 16-10-2009
Type Medicinal product subject to medical prescription
Marketing authorisation holder Merck Sharp & Dohme Ltd.